Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Another question submitted to shareholder forum

From the 10-Q, Note 6:

On September 19, 2013 the ‘890 patent was dropped from the N.D. Cal Case pursuant to stipulation by all parties. A jury trial was held in the N.D. Cal. Case against HTC, beginning on September 23, 2013. On October 3, 2013, the jury returned a verdict in favor of us and TPL, finding that HTC had infringed the ‘336 patent with damages of $958,560. HTC has appealed the jury verdict and we have filed cross appeals regarding the period available for infringement damages related to the ‘890 patent. The parties met with a magistrate for a settlement conference on April 8, 2014. As a result of that meeting, information is being shared and the parties are scheduled to meet again on May 7, 2014.

What does it mean that we dropped the '890 from the case, but appealed "regarding the period available for infringement damages related to the '890 patent" ?

Also note, a settlement conference is scheduled for May 7 on both the HTC appeal and this '890 issue.

Share
New Message
Please login to post a reply